Population-based SEER trend analysis of overall and cancer-specific survival in 5138 patients with gastrointestinal stromal tumor

被引:47
作者
Gueller, Ulrich [1 ,2 ]
Tarantino, Ignazio [3 ]
Cerny, Thomas [1 ]
Schmied, Bruno M. [4 ]
Warschkow, Rene [4 ,5 ]
机构
[1] Kantonsspital St Gallen, Div Med Oncol & Hematol, CH-9007 St Gallen, Switzerland
[2] Univ Hosp Berne, Univ Clin Visceral Surg & Med, CH-3010 Bern, Switzerland
[3] Heidelberg Univ, Dept Gen Abdominal & Transplant Surg, D-69120 Heidelberg, Germany
[4] Kantonsspital St Gallen, Dept Surg, CH-9007 St Gallen, Switzerland
[5] Heidelberg Univ, Inst Med Biometry & Informat, D-69120 Heidelberg, Germany
关键词
Gastrointestinal stromal tumors (GIST); Surveillance; Epidemiology and End Results (SEER) database; Trend analysis; Gastric GIST; ADJUVANT IMATINIB; RANDOMIZED-TRIAL; TYROSINE KINASE; EPIDEMIOLOGY; MESYLATE; SPAIN; GIST;
D O I
10.1186/s12885-015-1554-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The objective of the present population-based analysis was to assess survival patterns in patients with resected and metastatic GIST. Methods: Patients with histologically proven GIST were extracted from the Surveillance, Epidemiology and End Results (SEER) database from 1998 through 2011. Survival was determined applying Kaplan-Meier-estimates and multivariable Cox-regression analyses. The impact of size and mitotic count on survival was assessed with a generalized receiver-operating characteristic-analysis. Results: Overall, 5138 patients were included. Median age was 62 years (range: 18-101 years), 47.3 % were female, 68.8 % Caucasians. GIST location was in the stomach in 58.7 % and small bowel in 31.2 %. Lymph node and distant metastases were found in 5.1 and 18.0 %, respectively. For non-metastatic GIST, three-year overall survival increased from 68.5 % (95 % CI: 58.8-79.8 %) in 1998 to 88.6 % (95 % CI: 85.3-92.0 %) in 2008, cancer-specific survival from 75.3 % (95 % CI: 66.1-85.9 %) in 1998 to 92.2 % (95 % CI: 89.4-95.1 %) in 2008. For metastatic GIST, three-year overall survival increased from 15.0 % (95 % CI: 5.3-42.6 %) in 1998 to 54.7 % (95 % CI: 44.4-67.3 %) in 2008, cancer-specific survival from 15.0 % (95 % CI: 5.3-42.6 %) in 1998 to 61.9 % (95 % CI: 51.4-74.5 %) in 2008 (all P-Trend < 0.05). Conclusions: This is the first SEER trend analysis assessing outcomes in a large cohort of GIST patients over a 11-year time period. The analysis provides compelling evidence of a statistically significant and clinically relevant increase in overall and cancer-specific survival from 1998 to 2008, both for resected as well as metastatic GIST.
引用
收藏
页数:11
相关论文
共 24 条
[1]  
[Anonymous], 2014, SURV EP END RES PROG
[2]   Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 [J].
Blanke, Charles D. ;
Rankin, Cathryn ;
Demetri, George D. ;
Ryan, Christopher W. ;
von Mehren, Margaret ;
Benjamin, Robert S. ;
Raymond, A. Kevin ;
Bramwell, Vivien H. C. ;
Baker, Laurence H. ;
Maki, Robert G. ;
Tanaka, Michael ;
Hecht, J. Randolph ;
Heinrich, Michael C. ;
Fletcher, Christopher D. M. ;
Crowley, John J. ;
Borden, Ernest C. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :626-632
[3]   LOCALLY WEIGHTED REGRESSION - AN APPROACH TO REGRESSION-ANALYSIS BY LOCAL FITTING [J].
CLEVELAND, WS ;
DEVLIN, SJ .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1988, 83 (403) :596-610
[4]   Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial [J].
DeMatteo, Ronald P. ;
Ballman, Karla V. ;
Antonescu, Cristina R. ;
Maki, Robert G. ;
Pisters, Peter W. T. ;
Demetri, George D. ;
Blackstein, Martin E. ;
Blanke, Charles D. ;
von Mehren, Margaret ;
Brennan, Murray F. ;
Patel, Shreyaskumar ;
McCarter, Martin D. ;
Polikoff, Jonathan A. ;
Tan, Benjamin R. ;
Owzar, Kouros .
LANCET, 2009, 373 (9669) :1097-1104
[5]   Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial [J].
Demetri, George D. ;
van Oosterom, Allan T. ;
Garrett, Christopher R. ;
Blackstein, Martin E. ;
Shah, Manisha H. ;
Verweij, Jaap ;
McArthur, Grant ;
Judson, Ian R. ;
Heinrich, Michael C. ;
Morgan, Jeffrey A. ;
Desai, Jayesh ;
D Fletcher, Christopher ;
George, Suzanne ;
Bello, Carlo L. ;
Huang, Xin ;
Baum, Charles M. ;
Casali, Paolo G. .
LANCET, 2006, 368 (9544) :1329-1338
[6]   Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial [J].
Demetri, George D. ;
Reichardt, Peter ;
Kang, Yoon-Koo ;
Blay, Jean-Yves ;
Rutkowski, Piotr ;
Gelderblom, Hans ;
Hohenberger, Peter ;
Leahy, Michael ;
von Mehren, Margaret ;
Joensuu, Heikki ;
Badalamenti, Giuseppe ;
Blackstein, Martin ;
Le Cesne, Axel ;
Schoffski, Patrick ;
Maki, Robert G. ;
Bauer, Sebastian ;
Binh Bui Nguyen ;
Xu, Jianming ;
Nishida, Toshirou ;
Chung, John ;
Kappeler, Christian ;
Kuss, Iris ;
Laurent, Dirk ;
Casali, Paolo G. .
LANCET, 2013, 381 (9863) :295-302
[7]  
ESMO, 2012, ANN ONCOL, V23, P49, DOI [10.1093/annonc/mds252, DOI 10.1093/ANNONC/MDS252]
[8]   Diagnosis of gastrointestinal stromal tumors: A consensus approach [J].
Fletcher, CDM ;
Berman, JJ ;
Corless, C ;
Gorstein, F ;
Lasota, J ;
Longley, BJ ;
Miettinen, M ;
O'Leary, TJ ;
Remotti, H ;
Rubin, BP ;
Shmookler, B ;
Sobin, LH ;
Weiss, SW .
HUMAN PATHOLOGY, 2002, 33 (05) :459-465
[9]  
Fritz A, 2000, INT CLASSIFICATION D, P3
[10]   Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis [J].
Gold, Jason S. ;
Goenen, Mithat ;
Gutierrez, Antonio ;
Martin Broto, Javier ;
Garcia-del-Muro, Xavier ;
Smyrk, Thomas C. ;
Maki, Robert G. ;
Singer, Samuel ;
Brennan, Murray F. ;
Antonescu, Cristina R. ;
Donohue, John H. ;
DeMatteo, Ronald P. .
LANCET ONCOLOGY, 2009, 10 (11) :1045-1052